Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scleroderma, Systemic | 5 | 2022 | 43 | 1.430 |
Why?
|
| Parenting | 3 | 2014 | 19 | 1.160 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2014 | 35 | 0.830 |
Why?
|
| Mothers | 3 | 2014 | 190 | 0.800 |
Why?
|
| Disabled Persons | 2 | 2014 | 23 | 0.800 |
Why?
|
| Fanconi Anemia | 7 | 2020 | 14 | 0.750 |
Why?
|
| Neoplasms | 5 | 2016 | 141 | 0.690 |
Why?
|
| Child | 23 | 2022 | 2180 | 0.680 |
Why?
|
| Child, Preschool | 21 | 2022 | 1675 | 0.660 |
Why?
|
| Neuroblastoma | 3 | 2022 | 5 | 0.580 |
Why?
|
| Fanconi Anemia Complementation Group G Protein | 6 | 2020 | 11 | 0.570 |
Why?
|
| Liver Neoplasms | 2 | 2013 | 59 | 0.470 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2013 | 1 | 0.440 |
Why?
|
| Sarcoma | 1 | 2013 | 2 | 0.440 |
Why?
|
| Chronic Disease | 2 | 2014 | 100 | 0.430 |
Why?
|
| Adolescent | 18 | 2020 | 2858 | 0.430 |
Why?
|
| Liver | 1 | 2013 | 74 | 0.420 |
Why?
|
| Disease Management | 1 | 2013 | 73 | 0.420 |
Why?
|
| Infant | 13 | 2022 | 2145 | 0.410 |
Why?
|
| Child Rearing | 1 | 2010 | 2 | 0.370 |
Why?
|
| Humans | 27 | 2022 | 14077 | 0.370 |
Why?
|
| Health Education | 1 | 2011 | 35 | 0.360 |
Why?
|
| Rural Health | 1 | 2011 | 118 | 0.350 |
Why?
|
| Female | 20 | 2021 | 8751 | 0.350 |
Why?
|
| Mother-Child Relations | 1 | 2009 | 20 | 0.310 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 247 | 0.310 |
Why?
|
| Disability Evaluation | 3 | 2016 | 20 | 0.310 |
Why?
|
| Fatigue | 3 | 2014 | 20 | 0.300 |
Why?
|
| Surveys and Questionnaires | 4 | 2016 | 532 | 0.290 |
Why?
|
| South Africa | 15 | 2021 | 7312 | 0.230 |
Why?
|
| Male | 16 | 2021 | 6489 | 0.230 |
Why?
|
| Middle Aged | 6 | 2017 | 3425 | 0.230 |
Why?
|
| Adult | 7 | 2017 | 5664 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2022 | 767 | 0.220 |
Why?
|
| Mutation | 3 | 2020 | 299 | 0.220 |
Why?
|
| Infant, Newborn | 5 | 2016 | 1410 | 0.210 |
Why?
|
| Scleroderma, Diffuse | 1 | 2022 | 7 | 0.200 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2022 | 7 | 0.200 |
Why?
|
| Activities of Daily Living | 2 | 2012 | 39 | 0.190 |
Why?
|
| Thyroid Hormones | 1 | 2020 | 2 | 0.180 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2020 | 2 | 0.180 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 5 | 0.180 |
Why?
|
| National Health Programs | 1 | 2021 | 78 | 0.180 |
Why?
|
| Insulin | 1 | 2020 | 72 | 0.170 |
Why?
|
| Incidence | 5 | 2016 | 655 | 0.170 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 230 | 0.150 |
Why?
|
| Radiation, Ionizing | 1 | 2017 | 1 | 0.150 |
Why?
|
| Mitomycin | 1 | 2017 | 1 | 0.150 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2017 | 1 | 0.150 |
Why?
|
| Micronucleus Tests | 1 | 2017 | 2 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 10 | 0.140 |
Why?
|
| Sequence Deletion | 2 | 2014 | 16 | 0.140 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 243 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2013 | 25 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 367 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2016 | 186 | 0.120 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 1377 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2021 | 939 | 0.120 |
Why?
|
| Pain | 1 | 2014 | 40 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 16 | 0.110 |
Why?
|
| Self Report | 1 | 2014 | 111 | 0.110 |
Why?
|
| Biopsy | 1 | 2013 | 37 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 58 | 0.110 |
Why?
|
| Survival Rate | 1 | 2013 | 96 | 0.110 |
Why?
|
| Mercaptopurine | 1 | 1992 | 1 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1992 | 3 | 0.100 |
Why?
|
| Prognosis | 3 | 2022 | 197 | 0.100 |
Why?
|
| Pain Measurement | 1 | 2012 | 15 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 405 | 0.100 |
Why?
|
| Patient Compliance | 1 | 1992 | 120 | 0.100 |
Why?
|
| Founder Effect | 4 | 2020 | 16 | 0.090 |
Why?
|
| Staining and Labeling | 1 | 2011 | 2 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2011 | 5 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2011 | 55 | 0.090 |
Why?
|
| Health Resources | 1 | 2011 | 65 | 0.090 |
Why?
|
| Health Status | 1 | 2010 | 111 | 0.090 |
Why?
|
| Homozygote | 2 | 2020 | 59 | 0.070 |
Why?
|
| Rural Population | 1 | 2011 | 624 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2017 | 34 | 0.060 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 8 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 7 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 20 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2021 | 149 | 0.060 |
Why?
|
| Young Adult | 3 | 2017 | 2357 | 0.060 |
Why?
|
| HIV Infections | 2 | 2014 | 4946 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2004 | 51 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 210 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2017 | 464 | 0.050 |
Why?
|
| Remission Induction | 1 | 2022 | 6 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 48 | 0.050 |
Why?
|
| United States | 1 | 2022 | 129 | 0.050 |
Why?
|
| Electroencephalography | 1 | 1981 | 9 | 0.050 |
Why?
|
| Cardiopulmonary Bypass | 1 | 1981 | 2 | 0.050 |
Why?
|
| Antineoplastic Protocols | 1 | 2021 | 4 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 8 | 0.050 |
Why?
|
| Hypothermia, Induced | 1 | 1981 | 14 | 0.050 |
Why?
|
| Puberty | 1 | 2020 | 22 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2020 | 106 | 0.040 |
Why?
|
| Age Factors | 1 | 2021 | 364 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1998 | 2 | 0.040 |
Why?
|
| Orbital Neoplasms | 1 | 1998 | 2 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 1998 | 2 | 0.040 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1998 | 2 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 1998 | 5 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1998 | 4 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2017 | 1 | 0.040 |
Why?
|
| Fanconi Anemia Complementation Group A Protein | 1 | 2017 | 1 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2017 | 4 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2017 | 4 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 5 | 0.040 |
Why?
|
| DNA Repair | 1 | 2017 | 11 | 0.040 |
Why?
|
| DNA Damage | 1 | 2017 | 12 | 0.040 |
Why?
|
| Hand | 1 | 2016 | 5 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2016 | 9 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 449 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 6 | 0.030 |
Why?
|
| Ear | 1 | 2013 | 2 | 0.030 |
Why?
|
| Eye Abnormalities | 1 | 2013 | 2 | 0.030 |
Why?
|
| Hand Deformities, Congenital | 1 | 2013 | 2 | 0.030 |
Why?
|
| Skin Pigmentation | 1 | 2013 | 4 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 4 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2013 | 3 | 0.030 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 1993 | 2 | 0.030 |
Why?
|
| Heterozygote | 1 | 2013 | 42 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1993 | 15 | 0.030 |
Why?
|
| Kidney | 1 | 2013 | 46 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 144 | 0.030 |
Why?
|
| Time Factors | 2 | 2011 | 503 | 0.030 |
Why?
|
| Methotrexate | 1 | 1992 | 17 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1992 | 32 | 0.030 |
Why?
|
| Administration, Oral | 1 | 1992 | 113 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 1992 | 31 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 1992 | 153 | 0.030 |
Why?
|
| Risk Factors | 1 | 2016 | 1431 | 0.020 |
Why?
|
| Aged | 1 | 2016 | 1650 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2011 | 4 | 0.020 |
Why?
|
| Burkitt Lymphoma | 1 | 2011 | 3 | 0.020 |
Why?
|
| Suburban Population | 1 | 2011 | 9 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 11 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 26 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 65 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 132 | 0.020 |
Why?
|
| Lost to Follow-Up | 1 | 2011 | 62 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 183 | 0.020 |
Why?
|
| Social Class | 1 | 2011 | 72 | 0.020 |
Why?
|
| Sarcoma, Kaposi | 1 | 2011 | 52 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 380 | 0.020 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2005 | 2 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2005 | 44 | 0.020 |
Why?
|
| Base Sequence | 1 | 2005 | 149 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 22 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 64 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2004 | 89 | 0.010 |
Why?
|
| Haplotypes | 1 | 2005 | 119 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 106 | 0.010 |
Why?
|
| Registries | 1 | 2004 | 89 | 0.010 |
Why?
|
| Africa South of the Sahara | 1 | 2005 | 328 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 217 | 0.010 |
Why?
|
| Developing Countries | 1 | 2004 | 385 | 0.010 |
Why?
|
| Body Temperature | 1 | 1981 | 7 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1981 | 25 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1998 | 25 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1998 | 24 | 0.010 |
Why?
|
| Acute Disease | 1 | 1998 | 105 | 0.010 |
Why?
|
| Cytogenetics | 1 | 1994 | 1 | 0.010 |
Why?
|
| Androgens | 1 | 1994 | 5 | 0.010 |
Why?
|
| Steroids | 1 | 1994 | 14 | 0.010 |
Why?
|
| Platelet Count | 1 | 1993 | 14 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1993 | 22 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1993 | 124 | 0.010 |
Why?
|